Molecular Discovery Research, GlaxoSmithKline Pharmaceuticals, New Frontiers Science Park (North), Third Avenue, Harlow, CM19 5AW, UK.
Schizophr Res. 2011 Apr;127(1-3):28-34. doi: 10.1016/j.schres.2010.12.009. Epub 2011 Jan 15.
We previously reported an association with a putative functional variant in the ADAMTSL3 gene, just below genome-wide significance in a genome-wide association study of schizophrenia. As variants impacting the function of ADAMTSL3 (a disintegrin-like and metalloprotease domain with thrombospondin type I motifs-like-3) could illuminate a novel disease mechanism and a potentially specific target, we have used complementary approaches to further evaluate the association. We imputed genotypes and performed high density association analysis using data from the HapMap and 1000 genomes projects. To review all variants that could potentially cause the association, and to identify additional possible pathogenic rare variants, we sequenced ADAMTSL3 in 92 schizophrenics. A total of 71 ADAMTSL3 variants were identified by sequencing, many were also seen in the 1000 genomes data, but 26 were novel. None of the variants identified by re-sequencing was in strong linkage disequilibrium (LD) with the associated markers. Imputation analysis refined association between ADAMTSL3 and schizophrenia, and highlighted additional common variants with similar levels of association. We evaluated the functional consequences of all variants identified by sequencing, or showing direct or imputed association. The strongest evidence for function remained with the originally associated variant, rs950169, suggesting that this variant may be causal of the association. Rare variants were also identified with possible functional impact. Our study confirms ADAMTSL3 as a candidate for further investigation in schizophrenia, using the variants identified here. The utility of imputation analysis is demonstrated, and we recommend wider use of this method to re-evaluate the existing canon of suggestive schizophrenia associations.
我们之前报道了在精神分裂症的全基因组关联研究中,ADAMTSL3 基因中一个假定的功能变异与精神分裂症存在关联,该关联接近全基因组显著性水平。由于影响 ADAMTSL3 功能的变异(一种具有血小板反应蛋白 I 型基序的解整合素样金属蛋白酶域样-3)可以阐明一种新的疾病机制和一个潜在的特异性靶点,我们使用互补方法进一步评估了这种关联。我们使用 HapMap 和 1000 基因组计划的数据进行了基因型推断和高密度关联分析。为了回顾所有可能导致这种关联的变异,并确定其他可能的致病稀有变异,我们对 92 名精神分裂症患者进行了 ADAMTSL3 测序。通过测序共鉴定了 71 个 ADAMTSL3 变异,其中许多也存在于 1000 基因组数据中,但有 26 个是新的。通过重新测序鉴定的变异均与关联标记无强连锁不平衡(LD)。重测序分析细化了 ADAMTSL3 与精神分裂症之间的关联,并突出了具有相似关联水平的其他常见变异。我们评估了通过测序或直接关联或推断关联鉴定的所有变异的功能后果。最强的功能证据仍然与最初关联的 rs950169 变异相关,这表明该变异可能是该关联的因果变异。还鉴定出了具有潜在功能影响的稀有变异。我们的研究使用这里鉴定的变异,证实了 ADAMTSL3 是进一步研究精神分裂症的候选基因。该研究还证明了推断分析的实用性,并建议更广泛地使用这种方法来重新评估现有的精神分裂症提示性关联的标准。